A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Date publication

septembre 2015

Journal

Oncoimmunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand

Tous les auteurs :
Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26405593

Résumé

Cutaneous T-cell lymphomas (CTCLs) represent a group of rarely occurring and clinically and pathologically heterogeneous diseases that are considered incurable at advanced stages. Current treatments provide limited clinical benefit and are thus largely amenable to improvement. An antibody-based CTCL-specific immunotherapy targeting the KIR3DL2 receptor expressed by the tumor cells in CTCL is currently under development and has shown encouraging results in pre-clinical studies.

Mots clés

Antibody, CTCL, KIR3DL2, immunotherapy, non-clinical studies

Référence

Oncoimmunology. 2015 09;4(9):e1022306